Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AVITA MedicalASX:AVH 60 Cash-to-Debt is 0.23 as of Jun. 2026, which is 99% below its 10-year median of 39.00. GuruFocus rates ASX:AVH with a GF Score™ of 60/100 and a GF Value™ of A$2.94 (Fairly Valued). The stock has 6 warning signs investors should review. Among 842 Medical Devices & Instruments companies, AVITA Medical ranks worse than 81.95% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. AVITA Medical's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.23.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, AVITA Medicalcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for AVITA Medical's Cash-to-Debt or its related term are showing as below:
ASX:AVH'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.23 Med: 39 Max: No Debt
Current: 0.23
During the past 13 years, AVITA Medical's highest Cash to Debt Ratio was No Debt. The lowest was 0.23. And the median was 39.00.
ASX:AVH's Cash-to-Debt is ranked worse than 81.95% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs ASX:AVH: 0.23
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
AVITA Medical Cash-to-Debt Related Terms
AVITA Medical Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for AVITA Medical's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:AVH vs TMCI, VMD, TLSI: Cash-to-Debt Comparison
For the Medical Devices subindustry, AVITA Medical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVITA Medical Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where AVITA Medical's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVITA Medical (ASX:AVH) has a Cash-to-Debt of 0.23 as of Jun. 2026. This is 99% below median its historical median of 39.00. Over the past decade, AVITA Medical's Cash-to-Debt has ranged from 0.23 to 10,000.00. According to the industry distribution chart, AVITA Medical ranks #690 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 81.9%.
Is AVITA Medical's Cash-to-Debt too high?
AVITA Medical's current Cash-to-Debt of 0.23 is 99% below median its 10-year median of 39.00. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. AVITA Medical's value of 0.23 is 85.9% below this industry median. Based on the distribution chart, AVITA Medical ranks #690 out of 842 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, AVITA Medical has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AVITA Medical's Cash-to-Debt compare to TMCI and VMD?
According to the Medical Devices & Instruments industry distribution chart, AVITA Medical ranks #690 out of 842 companies for Cash-to-Debt. This places AVITA Medical in the lower half of its industry. The industry median Cash-to-Debt is 1.64. AVITA Medical's value of 0.23 is 85.9% below this benchmark. Historically, AVITA Medical's own Cash-to-Debt has ranged from 0.23 to 10,000.00 over the past decade. While the company's 10-year median is 39.00 vs. the industry median of 1.64, AVITA Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AVITA Medical's current Cash-to-Debt of 0.23 is 85.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AVITA Medical's current Cash-to-Debt is 0.23, which is 99% below median its own 10-year median of 39.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AVITA Medical stock overvalued right now?
Based on GuruFocus' analysis, AVITA Medical (ASX:AVH) is currently considered Fairly Valued. The stock's GF Value™ is A$2.94, compared to a current price of A$2.70 — trading 8.2% below its estimated fair value. The current Cash-to-Debt is 0.23, which is 99% below median its 10-year median of 39.00 and 85.9% below the Medical Devices & Instruments industry median of 1.64. AVITA Medical's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For AVITA Medical (ASX:AVH), the current Cash-to-Debt is 0.23 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AVITA Medical (ASX:AVH) Overvalued in 2026?
Based on GuruFocus' analysis, AVITA Medical stock appears to be undervalued.
The current stock price of A$2.70 is trading 8.2% below its estimated GF Value™ of A$2.94.
GuruFocus considers AVITA Medical to be Fairly Valued.
Key valuation signals for ASX:AVH:
Cash-to-Debt: 0.23 (99% below median its 10-year median of 39.00)
GF Value™: A$2.94 vs. price of A$2.70 (8.2% below fair value)
Industry Position: 85.9% below the Medical Devices & Instruments median (#690 of 842)
No single metric tells the full story. See the ASX:AVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
60GF Score
Get the complete analysis for ASX:AVH
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVH has been successfully added to your 
